Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Shattuck Labs, Inc. STTK
$2.62
-$0.17 (-6.43%)
На 18:03, 12 мая 2023
+358.02%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
121352825.00000000
-
week52high
5.82
-
week52low
1.85
-
Revenue
652000
-
P/E TTM
-1
-
Beta
1.08659500
-
EPS
-2.32000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 12:30
Описание компании
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Needham | Buy | Buy | 12 авг 2022 г. |
| Citigroup | Buy | 01 июн 2022 г. | |
| HC Wainwright & Co. | Buy | 02 мая 2022 г. | |
| Needham | Buy | Buy | 16 мар 2022 г. |
| Berenberg | Buy | 14 апр 2021 г. | |
| BTIG | Buy | 31 авг 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Thomson Erin Ator | A | 48250 | 48250 | 25 янв 2023 г. |
| Thomson Erin Ator | A | 103209 | 24125 | 25 янв 2023 г. |
| Neill Andrew R | A | 69850 | 69850 | 25 янв 2023 г. |
| Neill Andrew R | A | 144416 | 34925 | 25 янв 2023 г. |
| Shukla Abhinav A. | A | 52200 | 52200 | 25 янв 2023 г. |
| Shukla Abhinav A. | A | 47092 | 26100 | 25 янв 2023 г. |
| Schreiber Taylor | D | 165050 | 165050 | 25 янв 2023 г. |
| DeYoung Casi | A | 54200 | 54200 | 25 янв 2023 г. |
| DeYoung Casi | A | 46880 | 27100 | 25 янв 2023 г. |
| Pandite Arundathy N. | A | 69750 | 69750 | 25 янв 2023 г. |
Новостная лента
Shattuck Labs, Inc. (STTK) Q3 2022 Earnings Call Transcript
Seeking Alpha
12 ноя 2022 г. в 06:47
Shattuck Labs, Inc. (NASDAQ:STTK ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Conor Richardson - Senior Director of Finance and Investor Relations Taylor Schreiber - Chief Executive Officer Lini Pandite - Chief Medical Officer Andrew Neill - Chief Financial Officer Conference Call Participants Marc Frahm - Cowen Gil Blum - Needham & Company Carly Kenselaar - Citi Kaveri Pohlman - BTIG Zhiqiang Shu - Berenberg Operator Good afternoon, everyone, and welcome to Shattuck Labs Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Shattuck Labs to Report Third Quarter 2022 Financial Results on November 8, 2022
GlobeNewsWire
01 ноя 2022 г. в 16:30
AUSTIN, TX and DURHAM, NC, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will report third quarter 2022 financial results and provide a general business overview on Tuesday, November 8, 2022.
Shattuck Labs to Present Updated Preclinical Data on Gamma Delta T Cell Engager (GADLEN) Platform Candidates at the Society for Immunotherapy of Cancer (SITC) Annual Meeting November 8-12
GlobeNewsWire
05 окт 2022 г. в 16:30
AUSTIN, TX & DURHAM, NC, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager (GADLEN) platform at SITC's 37th Annual Meeting being held November 8th – 12th, 2022, virtually and in-person in Boston.
Should You Buy Shattuck Labs (STTK) Ahead of Earnings?
Zacks Investment Research
13 мая 2022 г. в 10:32
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Shattuck Labs (STTK)
Zacks Investment Research
06 мая 2022 г. в 10:32
Shattuck Labs (STTK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.